The resignation of Food and Drug Administration (FDA) commissioner Scott Gottlieb adds further uncertainty to the future of federal oversight of CBD in the US ...
Start your FREE trial version
Sign up to access to our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.
